Le Lézard
Classified in: Health, Business
Subjects: AWD, SVY

PHARMASCIENCE MAKES GREAT PLACE TO WORK'S TOP 50 BEST WORKPLACES IN CANADA!


MONTREAL, April 30, 2024 /CNW/ - Pharmascience is thrilled to announce it has been included in Great Place to Work's Top 50 Best Workplaces in Canada 2024. Pharmascience is the only generic pharmaceutical company to be included in this list.

The Top 50 Best Workplaces in Canada is based on the results of an independent survey conducted by Great Place to Work. The survey involved 600,000 employees from 900 companies across the country. This list is based on various aspects of organizational culture, job satisfaction, benefits and professional development opportunities. Pharmascience stands out not only by its exceptional commitment to its employees, but also by its long-term, positive impact on the community and the health care sector.

Having earned a place in the Top 50 Best Workplaces in Canada, Pharmascience reinforces its commitment to excellence and consolidates its position as a top employer.

For more information on the top company rankings and to see the full report, visit the Great Place to Work website.

This distinction is the latest in a series of awards recently bestowed on Pharmascience, attesting to the company's excellent work environment and corporate culture:

Pharmascience would like to express its heartfelt thanks to all its employees. This achievement wouldn't have been possible without their dedication and commitment to the company.

About Pharmascience Inc.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,600 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 52nd among Canada's top 100 Research and Development (R&D) investors in 2023, with $40-50 million invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in employees and young people. Through various programs and initiatives, the company is dedicated to supporting their personal development and life. In 2024, the company was awarded Great Place to Work certification for the third consecutive year.

SOURCE Pharmascience Inc.


These press releases may also interest you

at 18:12
Functional Food Ingredients Market size is set to grow by USD 53.14 bn from 2024-2028, increased demand for functional food ingredients from probiotics segment to boost the market growth, Technavio
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
TOP-RANKED HEALTHCARE CONSULTING FIRM EXPANDS ROSTER, DEEPENS LEADERSHIP
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

More news about Health...


News published on and distributed by: